Therefore, selection of a treatment strategy adapted to an individual patient and disease determinants has become an increasingly complex process. The treatment landscape of MDS and AML has dramatically changed in the last few years, with the approval of several novel agents for subgroups of patients that harbor specific mutations, and the treatment of elderly patients has been revolutionized with the addition of venetoclax to hypomethylating agents (HMAs). Analysis of clinical outcomes across diverse practice settings has shown that patients with myeloid malignancies treated at academic or NCI-designated cancer centers with a subspecialty in these disorders have improved outcomes with lower odds of inpatient death or hospice discharge. The management of myeloid malignancies requires expertise with constant vigilance and readily available supportive care with transfusion of blood products, prevention of infections, and early recognition of sepsis. They comprise chronic stages such as ineffective hematopoiesis in the form of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms, and a more acute phase of acute myeloid leukemia (AML). Myeloid malignancies are a heterogeneous group of clonal bone marrow disorders characterized by clonal proliferation of hematopoietic stem or progenitor cells, recurrent genetic abnormalities, myelodysplasia, ineffective hematopoiesis, peripheral-blood cytopenia, and a varying risk of evolution to acute leukemia. With distance no longer being a limiting factor, elderly and frail cancer patients now had access to a larger provider network to seek opinions for their cancer care. To limit physical exposure of patients, telemedicine was rapidly adopted as a tool to continue caring for cancer patients. In March 2020, the COVID-19 pandemic led to a disruption of cancer care due to surging demands for healthcare resources as well as safety measures to control the spread of disease.